25 Results for "

MHCI

" in MedChemExpress (MCE) Product Catalog:
Products (25)

25 Results for "MHCI" in MCE Product Catalog:

  • Categories Recommended:
    More
Cat. No.: HY-P11397
CAS No.: 176510-49-9
Target:  

MHC

Research Areas:  

Cancer

VLPDVFIRCV, a melanoma antigen-derived peptide, is the intron sequence (nt 38-67) of the N-acetylglucosamine transferase V (GnT-V) gene. VLPDVFIRCV has a high affinity for MHC-I class molecules, but it cannot activate the immune response against natural tumor cells. The cytotoxic T lymphocytes (CTL) induced by VLPDVFIRCV can specifically lyse T2 cells loaded with this peptide in the chromium release experiment. VLPDVFIRCV can be used for vaccine design research .
loading...
    loading...
Cat. No.: HY-184499
CAS No.: 2420554-24-9
Target:  

MHC Aminopeptidase

Research Areas:  

Cancer

GRWD5769 is an orally potent ERAP1 inhibitor. GRWD5769 regulates the peptide repertoire presented by MHC-I, alters TCR diversity/clonality, reprograms antigen-experienced T cells, induces novel T cell responses, drives tumor cell killing, and alleviates T cell exhaustion. GRWD5769 can be used in the research of advanced solid malignancies, microsatellite-stable colorectal cancer, non-small cell lung cancer, bladder cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, and cervical cancer .
loading...
    loading...
Cat. No.: HY-181815
CAS No.: 1884222-37-0
Research Areas:  

Cancer

SBP-5147 is an orally active ULK1/ULK2 inhibitor, with an IC50 of 2 nM against ULK1 and an IC50 of 53 nM against ULK2. SBP-5147 inhibits the phosphorylation of Beclin-1 and Vps34, reduces autophagy flux, downregulates the expression of ATG13 and ATG101, upregulates the expression of MHC-I, induces caspase-dependent apoptosis, and decreases the viability of non-small cell lung cancer cells. SBP-5147 is applicable to research related to non-small cell lung cancer [1] .
loading...
    loading...
Cat. No.: HY-184379
CAS No.: 2358714-71-1
Target:  

HIV

Research Areas:  

Infection

SRI-37264 is a HIV-1 Nef inhibitor with a Kd value of 162 nM. SRI-37264 binds directly to HIV-1 Nef, disrupts the Nef·MHC-I·AP-1 μ1 complex, and inhibits the Nef-dependent enhancement of HIV-1 infectivity. SRI-37264 restores MHC-I expression on the surface of HIV-infected primary cells. SRI-37264 inhibits HIV-1 replication in primary macrophages. SRI-37264 is applicable to research related to HIV-1 infection .
loading...
    loading...
Cat. No.: HY-P992388

Target:  

LILRB

Research Areas:  

Cancer

IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
loading...
    loading...